Integer Holdings (ITGR)
(Delayed Data from NYSE)
$121.11 USD
+0.11 (0.09%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $121.11 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$121.11 USD
+0.11 (0.09%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $121.11 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth A Momentum B VGM
Zacks News
Amedisys Ties Up With Medalogix to Boost Home Health Unit
by Zacks Equity Research
Amedisys (AMED) pursues deals to boost Home Health business.
Cooper Companies (COO) Earnings Miss & Revenues Beat in Q3
by Zacks Equity Research
Cooper (COO) gains from solid CSI revenues in Q3; international revenues surge.
Here's Why You Should Invest in Veeva (VEEV) Stock Right Now
by Zacks Equity Research
Strong fundamentals and a solid Q2 aid Veeva (VEEV).
Glaukos (GKOS) Jumps: Stock Rises 7.2%
by Zacks Equity Research
Glaukos (GKOS) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Illumina MiSeq Dx Okayed in China, NGS Platform Gets a Boost
by Zacks Equity Research
Illumina's (ILMN) receipt of CNDA approval for MiSeq Dx Sequencing System is expected to expand customer base and boost the top line.
Here's Why You Should Invest in Phibro (PAHC) Right Now
by Zacks Equity Research
Phibro (PAHC) sees improvement across all segments. The Animal Health business has been a key contributor.
Patterson Companies (PDCO) Misses Q1 Earnings Estimates
by Zacks Equity Research
Patterson Companies' (PDCO) adjusted earnings declines considerably on a year-over-year basis in Q1. Lackluster performance by the dental unit is a concern.
Here's Why You Should Buy Inogen (INGN) Stock Right Now
by Zacks Equity Research
Inogen (INGN) gains from strong Q2 results and bright global prospects.
Here's Why You Should Invest in Genomic Health (GHDX) Now
by Zacks Equity Research
Genomic Health (GHDX) gains ground on growing adoption of prostate cancer test and solid international scenario.
Ecolab's Nalco Pairs With XOS to Boost Global Energy Unit
by Zacks Equity Research
Ecolab's (ECL) Nalco Champion's 3D CRUDEFLEX will integrate XOS' Clora Online; market prospects bright.
Here's Why You Should Hold On to Stryker (SYK) Stock Now
by Zacks Equity Research
Challenging global economic conditions and supply-side issues are major deterrents to Stryker's (SYK) top line in the near term. The company's significant exposure to robotics is a positive.
New Buyouts Aid Boston Scientific Amid Dull Pacemaker Sales
by Zacks Equity Research
Boston Scientific (BSX) continues to adopt organic as well as inorganic routes for success. However, sluggish global pacemaker sales continue to disappoint.
Phibro Animal (PAHC) Q4 Earnings Beat, Sales Improve Y/Y
by Zacks Equity Research
Phibro (PAHC) witnesses year-over-year improvement across all segments in Q4.
Wright Medical Buys Cartiva to Boost Lower Extremities Unit
by Zacks Equity Research
Wright Medical's (WMGI) addition of Synthetic Cartilage Implant is likely to drive revenues in 2019; raised guidance for 2018 encourages.
Here's Why You Should Hold On to DexCom (DXCM) Stock Now
by Zacks Equity Research
DexCom (DXCM) is expected to benefit from lucrative prospects in the diabetes market. However, the company's margins were under pressure in the last reported quarter.
STERIS (STE) Strategic Growth Strong, Competition a Woe
by Zacks Equity Research
STERIS' (STE) beneficial underlying market trends along with new product and service offerings are impressive. Meanwhile, the company worries over facing a severe competition.
Bruker to Expand Molecular Diagnostics Arm With Hain Buyout
by Zacks Equity Research
Hain's molecular diagnostics solutions of bacterial and viral infections are expected to compliment Bruker's (BRKR) MALDI Biotyper and IR Biotyper microbiology platforms.
Omnicell Patient Engagement Unit to Aid Medication Adherence
by Zacks Equity Research
Omnicell's (OMCL) revamped Patient Engagement platform likely to aid core Medication Adherence Unit; market looks promising.
Here's Why You Should Invest in Integer (ITGR) Stock Now
by Zacks Equity Research
Integer Holdings (ITGR) gains on strong quarterly performance. The company is likely to gain from the Cardio & Vascular, Neuromodulation and Non-Medical Electrochem markets.
Cerner, Duke Clinical Research Launch Risk Calculator App
by Zacks Equity Research
Cerner (CERN) launches new Risk Calculator app that will check cardiac risk. The company's relentless efforts to digitize its EHR systems is commendable.
Medtronic (MDT) Grows on CRHF Arm, Margin Pressure Ails
by Zacks Equity Research
Solid demand for Medtronic's (MDT) quadripolar cardiac resynchronization therapy-pacemakers (CRT-P) along with growth in Mechanical Circulatory Support drives Heart Failure division revenues.
Hill-Rom (HRC) Touches 52-Week High: What's Driving It?
by Zacks Equity Research
Hill-Rom (HRC) rides high on impressive Q3 results along with increased focus on product innovation through research and development.
Veeva Systems (VEEV) Q2 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Veeva Systems (VEEV) gains from its flagship Vault platform. Also, expanding margins are an added positive for the company.
Here's Why You Should Hold AmerisourceBergen (ABC) Stock Now (Revised)
by Zacks Equity Research
Strong performance in the World Courier Business is likely to provide AmerisourceBergen (ABC) a competitive edge in the MedTech space.
Align Technology International Growth Solid, Rivalry Rife
by Zacks Equity Research
Align Technology's (ALGN) Invisalign Technology prospects and growth in North America and outside hold great potential for the stock, particularly in the Asia-Pacific and EMEA regions.